The Interplay Between Obesity and the Renin–Angiotensin System: Molecular Insights and Therapeutic Perspectives
Novelty in Biomedicine,
Vol. 14 No. 4 (2026),
13 October 2026
,
Page 231-243
https://doi.org/10.22037/nbm.v14i4.53056
Abstract
Background and Aim: Obesity is a chronic multifactorial condition that is strongly associated with a wide range of cardiovascular and metabolic complications, including type 2 diabetes mellitus and metabolic syndrome. In addition to its well-established role in blood pressure regulation and electrolyte homeostasis, the renin–angiotensin system (RAS) has emerged as an important regulator of adipocyte biology, inflammatory signaling, oxidative stress, and systemic energy balance. In obesity, excessive activation of the RAS contributes to both metabolic and cardiovascular impairment, particularly through its effects on insulin resistance and chronic low-grade inflammation, supporting a reciprocal relationship between adiposity and RAS activity. This review summarizes current evidence on the obesity–RAS axis and evaluates the therapeutic potential of RAS-targeted strategies in obesity-related disorders.
Materials and Methods: A comprehensive review of the literature was undertaken to examine the role of RAS in obesity, with a particular focus on the interaction between the classical and counter-regulatory pathways, as well as the contribution of tissue-specific RAS to inflammation, insulin resistance, and metabolic dysfunction.
Results: Available evidence indicates that obesity is associated with increased angiotensin II production in adipose tissue, which promotes chronic inflammation, endothelial dysfunction, insulin resistance, and hypertension. Although central RAS activation may increase thermogenesis and reduce appetite, peripheral RAS activity appears to favor lipogenesis and metabolic deterioration. By contrast, the ACE2/angiotensin-(1–7)/Mas receptor axis exerts beneficial effects by improving vasodilatory capacity, enhancing insulin sensitivity and metabolic homeostasis, and attenuating oxidative stress and inflammatory responses. Consistent with these findings, pharmacological inhibition of the classical RAS, particularly with ACE inhibitors and angiotensin receptor blockers, has shown promising value in reducing obesity-associated metabolic and cardiovascular complications.
Conclusion: The relationship between obesity and the RAS is complex and bidirectional. Whereas activation of the classical RAS appears to drive disease progression, the counter-regulatory axis provides an important protective influence. Further studies are needed to refine RAS-based therapeutic strategies and to improve their clinical effectiveness in obesity-related metabolic disorders.
- Obesity
- Renin–angiotensin system
- Inflammation
- Insulin resistance
- Hypertension
- Therapeutic strategies
- Angiotensin II
How to Cite
References
1. Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022; 133:155217.
2. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and Cardiovascular Disease: A Scientific Statement from the American Heart Association. Circulation. 2021;143(21): e984–e1010.
3. Seke Etet PF, Vecchio L, Nwabo Kamdje AH, Mimche PN, Njamnshi AK, Adem A. Physiological and environmental factors affecting cancer risk and prognosis in obesity. Semin Cancer Biol. 2023; 94:50–61.
4. Mosquera-Sulbarán J, Ryder E, Vargas R, Pedreáñez A. Angiotensin II and human obesity. A narrative review of the pathogenesis. Invest Clin. 2022;63(4):435–53.
5. Pahlavani M, Kalupahana NS, Ramalingam L, Moustaid-Moussa N. Regulation and functions of the renin-angiotensin system in white and brown adipose tissue. Compr Physiol. 2017;7(4):1137–50.
6. Luo L, Liu M. Adipose tissue in control of metabolism. J Endocrinol. 2016;231(3): R77–R99.
7. Menikdiwela KR, Ramalingam L, Allen L, Scoggin S, Kalupahana NS, Moustaid-Moussa N. Angiotensin II Increases Endoplasmic Reticulum Stress in Adipose Tissue and Adipocytes. Sci Rep. 2019;9(1):8481.
8. Kuriakose J, Montezano AC, Touyz RM. ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease. Clin Sci (Lond). 2021;135(2):387–407.
9. Arendse LB, Danser AHJ, Poglitsch M, Touyz RM, Burnett JCJ, Llorens-Cortes C, et al. Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. Pharmacol Rev. 2019;71(4):539–70.
10. Nuttall FQ. Body Mass Index: Obesity, BMI, and Health: A Critical Review. Nutr Today. 2015;50(3):117–28.
11. Weir CB, Jan A. BMI Classification Percentile and Cutoff Points. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.
12. Wu Y, Li D, Vermund SH. Advantages and limitations of the body mass index (BMI) to assess adult obesity. Int J Environ Res Public Health. 2024;21(6):757.
13. Hruby A, Hu FB. The Epidemiology of Obesity: A Big Picture. Pharmacoeconomics. 2015;33(7):673–89.
14. Popkin BM, Ng SW. The nutrition transition to a stage of high obesity and noncommunicable disease prevalence dominated by ultra-processed foods is not inevitable. Obes Rev. 2022;23(1): e13366.
15. Chong B, Jayabaskaran J, Kong G, Chan YH, Chin YH, Goh R, et al. Trends and predictions of malnutrition and obesity in 204 countries and territories: an analysis of the Global Burden of Disease Study 2019. Lancet Reg Health West Pac. 2023; 32:100850.
16. Kalra S, Kapoor N, Verma M, Shaikh S, Das S, Jacob J, et al. Defining and Diagnosing Obesity in India: A Call for Advocacy and Action. J Obes. 2023; 2023:4178121.
17. Virolainen SJ, VonHandorf A, Viel KCMF, Weirauch MT, Kottyan LC. Gene-environment interactions and their impact on human health. Genes Immun. 2023;24(1):1–11.
18. Theodorakis N, Nikolaou M. The Human Energy Balance: Uncovering the Hidden Variables of Obesity. Nutrients. 2025;17(2):294.
19. Yang Z, Li N, Cui H, Liu B, Wang X, Zhang L, et al. Influence of the Interaction between Genetic Factors and Breastfeeding on Children’s Weight Status: A Systematic Review. Adv Nutr. 2024;15(11):100312.
20. Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017; 13:2231–41.
21. Ayers KL, Glicksberg BS, Garfield AS, Longerich S, White JA, Yang P, et al. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment. J Clin Endocrinol Metab. 2018;103(7):2601–12.
22. Smitka K, Papezova H, Vondra K, Hill M, Hainer V, Nedvidkova J. The role of “mixed” orexigenic and anorexigenic signals and autoantibodies reacting with appetite-regulating neuropeptides and peptides of the adipose tissue-gut-brain axis: relevance to food intake and nutritional status in patients with anorexia nervosa. Int J Endocrinol. 2013; 2013:483145.
23. Boua RP, Sorgho H, Rouamba T, Nakanabo Diallo S, Bognini JD, Konkobo SZ, et al. Gender differences in sociodemographic and behavioural factors associated with BMI in an adult population in rural Burkina Faso - an AWI-Gen sub-study. Glob Health Action. 2018;11(sup2):1527557.
24. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–98.
25. Sakers A, De Siqueira MK, Seale P, Villanueva CJ. Adipose-tissue plasticity in health and disease. Cell. 2022;185(3):419–46.
26. Piché ME, Tchernof A, Després JP. Obesity Phenotypes, Diabetes, and Cardiovascular Diseases. Circ Res. 2020;126(11):1477–500.
27. Tomiyama AJ, Carr D, Granberg EM, Major B, Robinson E, Sutin AR, et al. How and why weight stigma drives the obesity ‘epidemic’ and harms health. BMC Med. 2018;16(1):123.
28. Drager LF, McEvoy RD, Barbe F, Lorenzi-Filho G, Redline S. Sleep Apnea and Cardiovascular Disease: Lessons from Recent Trials and Need for Team Science. Circulation. 2017;136(19):1840–50.
29. Ashraf MJ, Baweja P. Obesity: the “huge” problem in cardiovascular diseases. Mo Med. 2013;110(6):499–504.
30. Cotter C, Walsh S. Cutaneous sequelae of a national health crisis: Obesity and the skin. Skin Health Dis. 2021;1(1): e7.
31. Rodríguez-Hernández H, Simental-Mendía LE, Rodríguez-Ramírez G, Reyes-Romero MA. Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Int J Endocrinol. 2013; 2013:678259.
32. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542(7640):177–85.
33. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):141–50.
34. Verma S, Hussain ME. Obesity and diabetes: An update. Diabetes Metab Syndr. 2017;11(1):73–9.
35. Zatterale F, Longo M, Naderi J, Raciti GA, Desiderio A, Miele C, et al. Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Front Physiol. 2019; 10:1607.
36. Ramalingam L, Menikdiwela K, LeMieux M, Dufour JM, Kaur G, Kalupahana N, et al. The renin angiotensin system, oxidative stress and mitochondrial function in obesity and insulin resistance. Biochim Biophys Acta Mol Basis Dis. 2017;1863(5):1106–14.
37. Cabandugama PK, Gardner MJ, Sowers JR. The renin angiotensin aldosterone system in obesity and hypertension: roles in the cardiorenal metabolic syndrome. Med Clin North Am. 2017;101(1):129–37.
38. Newgard CB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 2012;15(5):606–14.
39. Jiang SZ, Lu W, Zong XF, Ruan HY, Liu Y. Obesity and hypertension. Exp Ther Med. 2016;12(4):2395–9.
40. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991–1006.
41. DeMarco VG, Aroor AR, Sowers JR. The pathophysiology of hypertension in patients with obesity. Nat Rev Endocrinol. 2014;10(6):364–76.
42. Tan BL, Norhaizan ME. Effect of High-Fat Diets on Oxidative Stress, Cellular Inflammatory Response and Cognitive Function. Nutrients. 2019;11(11):2581.
43. Miller AJ, Arnold AC. The renin-angiotensin system in cardiovascular autonomic control: recent developments and clinical implications. Clin Auton Res. 2019;29(2):231–43.
44. Kanugula AK, Golledge J. Renin-Angiotensin System: Updated Understanding and Role in Physiological and Pathophysiological States. Int J Mol Sci. 2023;24(15):12242.
45. Sequeira-Lopez MLS, Gomez RA. Renin Cells, the Kidney, and Hypertension. Circ Res. 2021;128(7):887–907.
46. Triebel H, Castrop H. The renin angiotensin aldosterone system. Pflugers Arch. 2024;476(5):705–13.
47. Patel S, Rauf A, Khan H, Abu-Izneid T. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. Biomed Pharmacother. 2017; 94:317–25.
48. Persson PB. Renin: origin, secretion and synthesis. J Physiol. 2003;552(3):667–71.
49. Schary N, Edemir B, Todorov VT. A Possible Link between Cell Plasticity and Renin Expression in the Collecting Duct: A Narrative Review. Int J Mol Sci. 2024;25(17):9472.
50. Glenn ST, Jones CA, Gross KW, Pan L. Control of renin gene expression. Pflugers Arch. 2013;465(1):13–21.
51. Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical Renin-Angiotensin system in kidney physiology. Compr Physiol. 2014;4(3):1201–28.
52. Yamaguchi H, Gomez RA, Sequeira-Lopez MLS. Renin Cells, From Vascular Development to Blood Pressure Sensing. Hypertension. 2023;80(8):1580–9.
53. Aldehni F, Tang T, Madsen K, Plattner M, Schreiber A, Friis UG, et al. Stimulation of renin secretion by catecholamines is dependent on adenylyl cyclases 5 and 6. Hypertension. 2011;57(3):460–8.
54. Peti-Peterdi J, Harris RC. Macula densa sensing and signaling mechanisms of renin release. J Am Soc Nephrol. 2010;21(7):1093–6.
55. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2(7):247–57.
56. Saravi B, Li Z, Lang CN, Schmid B, Lang FK, Grad S, et al. The Tissue Renin-Angiotensin System and Its Role in the Pathogenesis of Major Human Diseases: Quo Vadis? Cells. 2021;10(3):650.
57. Shahid M, Rehman K, Akash MSH, Suhail S, Kamal S, Imran M, et al. Genetic Polymorphism in Angiotensinogen and Its Association with Cardiometabolic Diseases. Metabolites. 2022;12(12):1231.
58. de Kloet AD, Krause EG, Woods SC. The renin angiotensin system and the metabolic syndrome. Physiol Behav. 2010;100(5):525–34.
59. Alhawari H, Jarrar Y, Zihlif M, Wahbeh A, Alshelleh S, Alhabahbeh R, et al. The Association of M235T Genetic Polymorphism in Angiotensinogen Gene and Other Non-Genetic Factors with Essential Hypertension among Jordanian Patients. J Pers Med. 2024;14(3):284.
60. Guang C, Phillips RD, Jiang B, Milani F. Three key proteases–Angiotensin-I-converting enzyme (ACE), ACE2 and renin–within and beyond the renin-angiotensin system. Arch Cardiovasc Dis. 2012;105(6–7):373–85.
61. Froogh G, Pinto JT, Le Y, Kandhi S, Aleligne Y, Huang A, et al. Chymase-dependent production of angiotensin II: an old enzyme in old hearts. Am J Physiol Heart Circ Physiol. 2017;312(2):H223–H231.
62. Forrester SJ, Booz GW, Sigmund CD, Coffman TM, Kawai T, Rizzo V, et al. Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology. Physiol Rev. 2018;98(3):1627–738.
63. AlQudah M, Hale TM, Czubryt MP. Targeting the renin-angiotensin-aldosterone system in fibrosis. Matrix Biol. 2020;91–92:92–108.
64. Villapol S, Janatpour ZC, Affram KO, Symes AJ. The Renin Angiotensin System as a Therapeutic Target in Traumatic Brain Injury. Neurotherapeutics. 2023;20(6):1565–91.
65. Natarajan A, Jose PA. Renal Modulation: The Renin-Angiotensin-Aldosterone System (RAAS). In: Nephrology and Fluid/Electrolyte Physiology: Neonatology Questions and Controversies. Philadelphia: Saunders/Elsevier; 2008. p. 107–27.
66. Szczepanska-Sadowska E, Czarzasta K, Cudnoch-Jedrzejewska A. Dysregulation of the Renin-Angiotensin System and the Vasopressinergic System Interactions in Cardiovascular Disorders. Curr Hypertens Rep. 2018;20(3):19.
67. Varagic J, Ahmad S, Nagata S, Ferrario CM. ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep. 2014;16(3):420.
68. Fatima N, Patel SN, Hussain T. Angiotensin II Type 2 Receptor: A Target for Protection Against Hypertension, Metabolic Dysfunction, and Organ Remodeling. Hypertension. 2021;77(6):1845–56.
69. Sousa-Lopes A, de Freitas RA, Carneiro FS, Nunes KP, Allahdadi KJ, Webb RC, et al. Angiotensin (1-7) Inhibits Ang II-mediated ERK1/2 Activation by Stimulating MKP-1 Activation in Vascular Smooth Muscle Cells. Int J Mol Cell Med. 2020;9(1):50–61.
70. Dominici FP, Burghi V, Muñoz MC, Giani JF. Modulation of the action of insulin by angiotensin-(1–7). Clin Sci (Lond). 2014;126(9):613–30.
71. Ocaranza MP, Jalil JE. Protective Role of the ACE2/Ang-(1-9) Axis in Cardiovascular Remodeling. Int J Hypertens. 2012; 2012:594361.
72. Flores-Munoz M, Work LM, Douglas K, Denby L, Dominiczak AF, Graham D, et al. Angiotensin-(1-9) Attenuates Cardiac Fibrosis in the Stroke-Prone Spontaneously Hypertensive Rat via the Angiotensin Type 2 Receptor. Hypertension. 2012;59(2):300–7.
73. Norambuena-Soto I, Ocaranza MP, Cancino-Arenas N, Sanhueza-Olivares F, Villar-Fincheira P, Leiva-Navarrete S, et al. Angiotensin-(1–9) prevents vascular remodeling by decreasing vascular smooth muscle cell dedifferentiation through a FoxO1-dependent mechanism. Biochem Pharmacol. 2020; 180:114190.
74. Nádasy GL, Balla A, Dörnyei G, Hunyady L, Szekeres M. Direct Vascular Effects of Angiotensin II (A Systematic Short Review). Int J Mol Sci. 2025;26(1):412.
75. Zhang H, Han GW, Batyuk A, Ishchenko A, White KL, Patel N, et al. Structural basis for selectivity and diversity in angiotensin II receptors. Nature. 2017;544(7650):327–32.
76. Dasgupta C, Zhang L. Angiotensin II receptors and drug discovery in cardiovascular disease. Drug Discov Today. 2011;16(1–2):22–34.
77. de Carvalho Santuchi M, Dutra MF, Vago JP, Lima KM, Galvão I, de Souza-Neto FP, et al. Angiotensin-(1-7) and Alamandine Promote Anti-inflammatory Response in Macrophages in Vitro and in Vivo. Mediators Inflamm. 2019; 2019:2401081.
78. Marins FR, Limborço-Filho M, Oliveira ML, Qadri F, Bader M, Alenina N, et al. Alamandine but not angiotensin-(1-7) produces cardiovascular effects at the rostral insular cortex. Am J Physiol Regul Integr Comp Physiol. 2021;321(3): R513–R521.
79. Fernandes RS, Netto MRT, Carvalho FB, Rigatto K. Alamandine: A promising treatment for fibrosis. Peptides. 2022; 157:170848.
80. Gamiño-Gutiérrez JA, Terán-Hernández IM, Castellar-Lopez J, Villamizar-Villamizar W, Osorio-Llanes E, Palacios-Cruz M, et al. Novel Insights into the Cardioprotective Effects of the Peptides of the Counter-Regulatory Renin–Angiotensin System. Life. 2024;14(2):203.
81. Santos RAS, Oudit GY, Verano-Braga T, Canta G, Steckelings UM, Bader M. The renin-angiotensin system: going beyond the classical paradigms. Am J Physiol Heart Circ Physiol. 2019;316(5):H958–H970.
82. Garcia B, Zarbock A, Bellomo R, Legrand M. The alternative renin-angiotensin system in critically ill patients: pathophysiology and therapeutic implications. Crit Care. 2023;27(1):453.
83. Ferrario CM. Role of angiotensin II in cardiovascular disease - Therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst. 2006;7(1):3–14.
84. Castrop H, Höcherl K, Kurtz A, Schweda F, Todorov V, Wagner C. Physiology of Kidney Renin. Physiol Rev. 2010;90(2):607–73.
85. Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure. Circ Res. 2016;118(8):1313–26.
86. Mathieu NM, Nakagawa P, Grobe JL, Sigmund CD. Insights into the Role of Angiotensin-II AT1 Receptor-Dependent β-Arrestin Signaling in Cardiovascular Disease. Hypertension. 2024;81(1):6–16.
87. Gupta D, Kumar A, Mandloi A, Shenoy V. Renin angiotensin aldosterone system in pulmonary fibrosis: Pathogenesis to therapeutic possibilities. Pharmacol Res. 2021; 174:105924.
88. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020;126(10):1456–74.
89. Simões e Silva AC, Silveira KD, Ferreira AJ, Teixeira MM. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol. 2013;169(3):477–92.
90. Patel KP, Schultz HD. Angiotensin peptides and nitric oxide in cardiovascular disease. Antioxid Redox Signal. 2013;19(10):1121–32.
91. Paz Ocaranza M, Riquelme JA, García L, Jalil JE, Chiong M, Santos RAS, et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol. 2020;17(2):116–29.
92. Zheng J, Hao H. Targeting renal damage: The ACE2/Ang-(1–7)/mas axis in chronic kidney disease. Cell Signal. 2024; 124:111413.
93. Villela DC, Passos-Silva DG, Santos RAS. Alamandine: a new member of the angiotensin family. Curr Opin Nephrol Hypertens. 2014;23(2):130–4.
94. Zhu P, Verma A, Prasad T, Li Q. Expression and Function of Mas-Related G Protein-Coupled Receptor D and Its Ligand Alamandine in Retina. Mol Neurobiol. 2020;57(1):513–27.
95. Jesus ICG, Mesquita T, Souza Santos RA, Guatimosim S. An overview of alamandine/MrgD signaling and its role in cardiomyocytes. Am J Physiol Cell Physiol. 2023;324(3):C606–C613.
96. Putnam K, Shoemaker R, Yiannikouris F, Cassis LA. The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol. 2012;302(6):H1219–H1230.
97. Arabi T, Shafqat A, Sabbah BN, Fawzy NA, Shah H, Abdulkader H, et al. Obesity-related kidney disease: Beyond hypertension and insulin-resistance. Front Endocrinol (Lausanne). 2022; 13:1095211.
98. Bahar ME, Kim HJ, Kim DR. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. 2023;8(1):455.
99. Satou R, Penrose H, Navar LG. Inflammation as a Regulator of the Renin-Angiotensin System and Blood Pressure. Curr Hypertens Rep. 2018;20(12):100.
100. Liu C, Yang H, Shi W, Wang T, Ruan Q. MicroRNA-mediated regulation of T helper type 17/regulatory T-cell balance in autoimmune disease. Immunology. 2018;155(4):427–34.
101. Ji Y, Liu J, Wang Z, Liu N. Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem. 2009;23(4–6):265–76.
102. Ávila-Martínez DV, Mixtega-Ruiz WK, Hurtado-Capetillo JM, Lopez-Franco O, Flores-Muñoz M. Counter-regulatory RAS peptides: new therapy targets for inflammation and fibrotic diseases? Front Pharmacol. 2024; 15:1356891.
103. Nehme A, Zouein FA, Zayeri ZD, Zibara K. An update on the tissue renin angiotensin system and its role in physiology and pathology. J Cardiovasc Dev Dis. 2019;6(2):14.
104. Ting R, Dutton H, Sorisky A. In vitro studies of the renin-angiotensin system in human adipose tissue/adipocytes and possible relationship to SARS-CoV-2: a scoping review. Adipocyte. 2023;12(1):2194034.
105. Kirichenko TV, Markina YV, Bogatyreva AI, Tolstik TV, Varaeva YR, Starodubova AV. The Role of Adipokines in Inflammatory Mechanisms of Obesity. Int J Mol Sci. 2022;23(23):14943.
106. Ames MK, Atkins CE, Pitt B. The renin-angiotensin-aldosterone system and its suppression. J Vet Intern Med. 2019;33(2):363–82.
107. Shariq OA, McKenzie TJ. Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery. Gland Surg. 2020;9(1):80–93.
108. Smith MM, Minson CT. Obesity and adipokines: effects on sympathetic overactivity. J Physiol. 2012;590(8):1787–801.
109. King VL, English VL, Bharadwaj K, Cassis LA. Angiotensin II Stimulates Sympathetic Neurotransmission to Adipose Tissue. Physiol Rep. 2013;1(2):e00028.
110. Merz KE, Thurmond DC. Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake. Compr Physiol. 2020;10(3):785–809.
111. Mitchell CS, Begg DP. Inhibition of the renin-angiotensin system reduces gene expression of inflammatory mediators in adipose tissue independent of energy balance. Front Endocrinol (Lausanne). 2021; 12:682726.
112. Kalupahana NS, Massiera F, Quignard-Boulange A, Ailhaud G, Voy BH, Wasserman DH, et al. Overproduction of angiotensinogen from adipose tissue induces adipose inflammation, glucose intolerance, and insulin resistance. Obesity (Silver Spring). 2012;20(1):48–56.
113. Jia N, Gao Y, Li M, Liang Y, Li Y, Lin Y, et al. Metabolic reprogramming of proinflammatory macrophages by target delivered roburic acid effectively ameliorates rheumatoid arthritis symptoms. Signal Transduct Target Ther. 2023;8(1):280.
114. Guo C, Sun L, Chen X, Zhang D. Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regen Res. 2013;8(21):2003–14.
115. Jha R, Lopez-Trevino S, Kankanamalage HR, Jha JC. Diabetes and Renal Complications: An Overview on Pathophysiology, Biomarkers and Therapeutic Interventions. Biomolecules. 2024;14(5):548.
116. Chen S, Li Q, Shi H, Li F, Duan Y, Guo Q. New insights into the role of mitochondrial dynamics in oxidative stress-induced diseases. Biomed Pharmacother. 2024; 178:117084.
117. Zhao X, An X, Yang C, Sun W, Ji H, Lian F. The crucial role and mechanism of insulin resistance in metabolic disease. Front Endocrinol (Lausanne). 2023; 14:1149239.
118. McFall A, Nicklin SA, Work LM. The counter regulatory axis of the renin angiotensin system in the brain and ischaemic stroke: Insight from preclinical stroke studies and therapeutic potential. Cell Signal. 2020; 76:109809.
119. Vernail VL, Lucas L, Miller AJ, Arnold AC. Angiotensin-(1-7) and Central Control of Cardiometabolic Outcomes: Implications for Obesity Hypertension. Int J Mol Sci. 2024;25(24):13245.
120. Heyman SN, Walther T, Abassi Z. Angiotensin-(1-7)-A Potential Remedy for AKI: Insights Derived from the COVID-19 Pandemic. J Clin Med. 2021;10(6):1228.
121. Grobe JL, Rahmouni K, Liu X, Sigmund CD. Metabolic rate regulation by the renin-angiotensin system: brain vs. body. Pflugers Arch. 2013;465(1):167–75.
- Abstract Viewed: 2 times
- pdf Downloaded: 0 times